Dave - I think they got excited, did a PR and then had everyone asking, where is it? This is exactly what people wanted Amarantus to do, hype before you could deliver and hasn't worked out for Nanosomix. This is why you see the later statements that they are a long ways off made by the company. Glad the said it and Gerald didn't have to explain it.

If you dig into the details there is a big difference between a case control study which is what they did vs. a full cohort study which is what Amarantus did. What is quick, cheap and easy. The other is what the scientific community and BP require.

Case-control study - http://en.wikipedia.org/wiki/Case-control_study

Cohort study - http://en.wikipedia.org/wiki/Cohort_study